The present invention relates to a cryoprotecting agent comprising a cryprotectant being one or more of: dextrin, dextran, isomaltooligosaccharide and derivatives thereof, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation.

A thermal capacitor includes a shell and a PCM. The shell includes a first major surface that is configured to contact a container including media to be frozen. The shell defines a cavity in which the PCM is disposed. The PCM has a transition temperature in a range of −80 degrees Celsius to −50 degrees Celsius and is configured to rapidly freeze media from room temperature to −60 degrees Celsius with the container including the media in contact with the shell in an enclosed space.

A carrier for receiving a vessel includes a body that defines a well. The well is sized and dimensioned to receive a vessel including media. The body is configured to urge the vessel received in the well towards an external wall of the body to enhance thermal energy transfer into or out of the media within the vessel. A box assembly for supporting media during thermal changes includes a box, a vessel, and a carrier is also disclosed.

A free radical sterilization system having a chamber defining a region, and a generator for generating free radical reach effluent from a free radical electric generator and/or a vaporizer. A closed loop circulating system without a free-radical destroyer is provided for supplying the mixture of free radicals from the electric generator mixed with the hydrogen peroxide solution in the form of the effluent to the chamber. The free-radical sterilization system is used in sterilizing items in the chamber and, with an open-bottomed wound chamber, in treating wounds on a body.

The invention relates to an artificial womb system for supporting newborns, in particular extremely premature infants between the 21/0 and 28/0 week of pregnancy, comprising the following: a chamber (1) of the artificial womb, said chamber being formed by an at least partially ultrasound-permeable wall (2) and comprising a lumen (14) for maintaining a physiologically intraamnial pressure and for receiving the artificial amniotic fluid (15) and a newborn or a premature infant, at least one access for supplying the premature infant in the artificial womb with nutrients, a dialysis device (9), and an oxygenator (8) and/or a gassing device for supplying oxygen to the newborn or premature infant, wherein means are provided in order to maintain an intraamnial pressure of >0 mBar in the chamber (1) of the artificial womb, said pressure acting on the newborn, in addition to the atmospheric pressure.

A corneal storage composition is disclosed. The composition comprises a buffered, balanced, nutrient and electrolyte aqueous solution; γ-PGA; and ferulic acid, in amounts effective to maintain cell integrity and viability of the corneal tissue for a period of greater than 14 days.

The present disclosure provides for a cell stabilizing medium which comprises gelatin. The cell stabilizing medium help maintain cell viability, e.g., after thawing of a biological material post-cryopreservation.

A method for stabilizing and isolating multiple biological targets comprised in a cell-containing bodily fluid, said method comprising (A) contacting a cell-containing bodily fluid with a stabilizing composition comprising one or more of the following stabilizing agents: (a) at least one primary, secondary or tertiary amide, (b) at least one poly(oxyethylene) polymer, and/or (c) at least one apoptosis inhibitor, thereby providing a stabilized cell-containing bodily fluid sample; (B) keeping the stabilized cell-containing bodily fluid sample for a stabilization period; and (C) processing the stabilized cell-containing bodily fluid sample in order to enrich three or more biological targets selected from the group consisting of —a cell subpopulation, —extracellular nucleic acids, —extracellular vesicles and —intracellular nucleic acids from the stabilized cell-containing bodily fluid. The method is advantageous and enables the multimodal analyses of different biological targets from a single stabilized cell-containing body fluid sample.

An organ perfusion system (100) for extracorporeal perfusion of a heart (1) includes an organ chamber (15) having an aortic connector (17), and a first fluid flow path (19) comprising a pump interface (23) and an oxygenator (25), the aortic connector being fluidly connected to the first fluid flow path. The system is adapted for use in a method, wherein oxygenated perfusate is flowed into the heart via the aorta and desoxygenated perfusate is allowed to exit the heart via the inferior vena cava and/or the superior vena cava to thereby perfuse the heart in a substantially unloaded state. Such method may allow for improved recovery of the heart tissue during perfusion. The organ perfusion system may further comprise a perfusate reservoir (27) and/or a chassis, wherein the organ chamber is pivotable with respect to the chassis for holding the heart in a tilted position or to allow rotation of the organ chamber in a horizontal plane.

An aqueous storage solution for the storage of red blood cells, comprising an aqueous solution and at least one lipid, wherein the at least one lipid is effective in suppressing hemolysis in red blood cells and wherein the at least one lipid is emulsified within the aqueous solution.